Physician profile
Ruemu E Birhiray
NPI 1295735058
$3,055,048.12
in general payments reported to CMS, 2019-2025
100 companies · $435K in 2025
The $435K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $402K · 2020: $237K · 2021: $475K · 2022: $481K · 2023: $542K · 2024: $484K · 2025: $435K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $981K · Travel and Lodging: $235K · Consulting Fee: $140K · Food and Beverage: $41K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $39K · Honoraria: $24K · Education: $477 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $981,079.73 |
| Travel and Lodging | $235,167.48 |
| Consulting Fee | $140,190.50 |
| Food and Beverage | $40,937.96 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $38,530.00 |
| Honoraria | $23,847.67 |
| Education | $477.41 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $429,304.34 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Incyte Corporation | $416,217.93 | 2019-2025 | Monjuvi, Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals Lp | $246,328.58 | 2019-2025 | Enhertu, Datroway, Calquence |
| Amgen INC. | $230,057.26 | 2019-2025 | Lumakras, Imdelltra (Amg757), Nplate |
| Lilly USA, LLC | $194,570.99 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $160,476.36 | 2019-2025 | Nerlynx |
| Pharmacyclics LLC, An Abbvie Company | $130,700.09 | 2019-2023 | Imbruvica, Epkinly |
| Seagen INC. | $122,647.94 | 2019-2023 | Tukysa, Adcetris |
| Glaxosmithkline, LLC. | $106,004.33 | 2020-2025 | Ojjaara, Blenrep, Zejula |
| Exelixis INC. | $86,559.82 | 2019-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $85,019.49 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Genzyme Corporation | $77,876.31 | 2019-2025 | |
| Beigene USA, INC. | $76,010.32 | 2023-2025 | Brukinsa, Tevimbra |
| Abbvie INC. | $67,839.15 | 2019-2025 | Venclexta |
| Stemline Therapeutics INC. | $65,549.35 | 2023-2025 | Orserdu |
Show all 100 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $56,088.41 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $50,023.99 | 2019-2025 | Kisqali, Piqray |
| Dova Pharmaceuticals | $44,986.30 | 2019-2021 | |
| Daiichi Sankyo INC. | $39,469.61 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Regeneron Healthcare Solutions, INC. | $38,953.73 | 2019-2025 | Libtayo |
| Taiho Oncology, INC. | $34,916.65 | 2020-2025 | |
| Genmab U.S., INC. | $23,649.85 | 2023-2025 | Epkinly, Tivdak |
| Blueprint Medicines Corporation | $19,795.72 | 2022-2025 | Ayvakit |
| Astellas Pharma US INC | $19,113.87 | 2020-2025 | Xtandi, Padcev, Xospata |
| Beone Medicines USA, INC. | $18,329.35 | 2025 | Brukinsa |
| Sanofi US Services INC. | $15,351.17 | 2025 | |
| Adc Therapeutics America, INC. | $14,901.87 | 2022-2025 | |
| Tesaro, INC. | $13,660.99 | 2019 | |
| Eli Lilly and Company | $13,397.87 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $11,325.34 | 2020-2025 | Xpovio |
| Cti Biopharma Corp. | $11,307.80 | 2022-2023 | Vonjo |
| Pfizer INC. | $10,979.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,730.00 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Ipsen Biopharmaceuticals, INC | $8,916.85 | 2019-2025 | Tazverik, Somatuline Depot, Onivyde |
| Pharmacosmos Therapeutics INC. | $8,580.34 | 2023-2025 | Monoferric |
| Kite Pharma, INC. | $8,159.44 | 2022-2025 | Yescarta |
| Morphosys, US INC. | $8,053.73 | 2021-2023 | Monjuvi |
| Gilead Sciences, INC. | $8,012.37 | 2019-2025 | Trodelvy |
| Syndax Pharmaceuticals, INC. | $7,335.35 | 2025 | |
| Genentech, INC. | $7,171.26 | 2023 | Venclexta |
| Rigel Pharmaceuticals, INC. | $6,841.56 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Janssen Scientific Affairs, LLC | $6,771.86 | 2019-2023 | Imbruvica, Darzalex |
| Regeneron Pharmaceuticals, INC. | $5,844.66 | 2024-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $5,227.07 | 2019-2025 | |
| Coherus Oncology, INC. | $4,880.14 | 2021-2024 | |
| Astellas Pharma Global Development | $4,650.00 | 2020 | |
| Genentech USA, INC. | $4,512.66 | 2019-2025 | Venclexta, Polivy, Phesgo |
| Celgene Corporation | $3,963.33 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Invivyd INC | $2,817.50 | 2025 | Pemgarda |
| Novocure INC. | $2,292.43 | 2024 | Optune Lua (Novottf-200t) |
| Tg Therapeutics, INC. | $2,025.00 | 2021 | |
| Array Biopharma INC | $996.88 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Merck Sharp & Dohme LLC | $908.06 | 2019-2025 | Keytruda, Reblozyl, Lynparza |
| Spectrum Pharmaceuticals INC. | $750.00 | 2023 | Rolvedon |
| Tersera Therapeutics LLC | $716.82 | 2019-2025 | Zoladex, Xermelo |
| Eisai INC. | $522.99 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $494.46 | 2022-2023 | Myrisk |
| Acrotech Biopharma INC. | $315.08 | 2021-2025 | Beleodaq |
| Adaptive Biotechnologies Corporation | $260.29 | 2023-2025 | Clonoseq |
| Legend Biotech USA INC. | $200.43 | 2024-2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $195.36 | 2019-2025 | Ultomiris |
| Fennec Pharmaceuticals, INC. | $188.69 | 2024 | Pedmark |
| Servier Pharmaceuticals LLC | $185.12 | 2024-2025 | |
| Accord Healthcare, INC. | $173.69 | 2025 | |
| Apellis Pharmaceuticals, INC. | $144.54 | 2021-2023 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.07 | 2019-2025 | |
| Geron Corporation | $139.92 | 2025 | Rytelo |
| Emd Serono, INC. | $125.74 | 2019-2025 | |
| Secura Bio, INC. | $107.84 | 2021 | |
| Sumitomo Pharma America, INC. | $107.80 | 2023-2024 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $104.89 | 2025 | |
| Kyowa Kirin, INC. | $82.72 | 2023-2025 | Poteligeo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Focal Therapeutics, INC. | $79.54 | 2019 | |
| Menarini Silicon Biosystems, INC. | $76.14 | 2023-2025 | |
| Stryker Corporation | $66.25 | 2025 | Clottriever Bold Catheter |
| Mirati Therapeutics, INC. | $64.37 | 2023-2024 | Krazati |
| Caris Mpi, INC. | $62.53 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $54.58 | 2023-2025 | |
| Springworks Therapeutics, INC. | $44.73 | 2025 | Gomekli |
| Recordati_rare_diseases_inc. | $43.17 | 2025 | Enjaymo, Sylvant |
| Pharmaessentia USA Corporation | $40.90 | 2024-2025 | Besremi |
| Myovant Sciences INC. | $34.94 | 2022 | |
| Organon LLC | $34.93 | 2024 | |
| Foundation Medicine, INC. | $30.55 | 2019 | |
| Clovis Oncology, INC. | $30.04 | 2019 | |
| Verity Pharmaceuticals INC. | $27.77 | 2023 | Trelstar |
| Deciphera Pharmaceuticals INC. | $27.74 | 2021-2023 | Qinlock |
| Helsinn Therapeutics (U.S.), INC. | $27.05 | 2019 | |
| Pharming Healthcare, INC. | $18.98 | 2024 | Ruconest |
| Sun Pharmaceutical Industries INC. | $18.29 | 2023 | Yonsa, Odomzo |
| Amneal Pharmaceuticals LLC | $17.97 | 2025 | Pemrydi Rtu |
| Agios Pharmaceuticals, INC. | $15.80 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.15 | 2025 | Vivimusta |
| Teva Pharmaceuticals USA, INC. | $13.98 | 2020 | |
| Biocon Biologics INC | $13.88 | 2025 | Ogivri |
| Sandoz INC. | $11.78 | 2019 | |
| Iovance Biotherapeutics, INC. | $11.24 | 2025 | Amtagvi |
| Veracyte, INC. | $8.18 | 2023 | |
| Janssen Pharmaceuticals, INC | $7.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,975.87 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruemu Birhiray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.